Cargando…

Postobstructive Pneumonia: An Underdescribed Syndrome

Background. Postobstructive community-acquired pneumonia (PO-CAP) is relatively common in clinical practice. The clinical syndrome is poorly defined, and the role of infection as a cause of the infiltrate is uncertain. We prospectively studied patients with PO-CAP and compared them to a cohort of pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Abers, Michael S., Sandvall, Barcleigh P., Sampath, Rahul, Zuno, Carlo, Uy, Natalie, Yu, Victor L., Stager, Charles E., Musher, Daniel M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4803103/
https://www.ncbi.nlm.nih.gov/pubmed/26908806
http://dx.doi.org/10.1093/cid/civ1212
_version_ 1782422838658990080
author Abers, Michael S.
Sandvall, Barcleigh P.
Sampath, Rahul
Zuno, Carlo
Uy, Natalie
Yu, Victor L.
Stager, Charles E.
Musher, Daniel M.
author_facet Abers, Michael S.
Sandvall, Barcleigh P.
Sampath, Rahul
Zuno, Carlo
Uy, Natalie
Yu, Victor L.
Stager, Charles E.
Musher, Daniel M.
author_sort Abers, Michael S.
collection PubMed
description Background. Postobstructive community-acquired pneumonia (PO-CAP) is relatively common in clinical practice. The clinical syndrome is poorly defined, and the role of infection as a cause of the infiltrate is uncertain. We prospectively studied patients with PO-CAP and compared them to a cohort of patients with bacterial community-acquired pneumonia (B-CAP). Methods. We prospectively studied patients hospitalized for CAP; 5.4% had PO-CAP, defined as a pulmonary infiltrate occurring distal to an obstructed bronchus. Sputum and blood cultures, viral polymerase chain reaction, urinary antigen tests, and serum procalcitonin (PCT) were done in nearly all cases. Clinical and laboratory characteristics of patients with PO-CAP were compared to those of patients with B-CAP. Results. In a 2-year period, we identified 30 patients with PO-CAP. Compared to patients with B-CAP, patients with PO-CAP had longer duration of symptoms (median, 14 vs 5 days; P < .001). Weight loss and cavitary lesions were more common (P < .01 for both comparisons) and leukocytosis was less common (P < .01) in patients with PO-CAP. A bacterial pathogen was implicated in only 3 (10%) PO-CAP cases. PCT was <0.25 ng/mL in 19 (63.3%) patients. Although no differences were observed in disease severity or rates of intensive care unit admissions, 30-day mortality was significantly higher in PO-CAP vs B-CAP (40.0% vs 11.7%; P < .01). Conclusions. Although there is substantial overlap, PO-CAP is a clinical entity distinct from B-CAP; a bacterial cause was identified in only 10% of patients. Our study has important implications for the clinical recognition of patients with PO-CAP, the role of microorganisms as etiologic agents, and the use of antibiotic therapy.
format Online
Article
Text
id pubmed-4803103
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-48031032017-04-15 Postobstructive Pneumonia: An Underdescribed Syndrome Abers, Michael S. Sandvall, Barcleigh P. Sampath, Rahul Zuno, Carlo Uy, Natalie Yu, Victor L. Stager, Charles E. Musher, Daniel M. Clin Infect Dis Articles and Commentaries Background. Postobstructive community-acquired pneumonia (PO-CAP) is relatively common in clinical practice. The clinical syndrome is poorly defined, and the role of infection as a cause of the infiltrate is uncertain. We prospectively studied patients with PO-CAP and compared them to a cohort of patients with bacterial community-acquired pneumonia (B-CAP). Methods. We prospectively studied patients hospitalized for CAP; 5.4% had PO-CAP, defined as a pulmonary infiltrate occurring distal to an obstructed bronchus. Sputum and blood cultures, viral polymerase chain reaction, urinary antigen tests, and serum procalcitonin (PCT) were done in nearly all cases. Clinical and laboratory characteristics of patients with PO-CAP were compared to those of patients with B-CAP. Results. In a 2-year period, we identified 30 patients with PO-CAP. Compared to patients with B-CAP, patients with PO-CAP had longer duration of symptoms (median, 14 vs 5 days; P < .001). Weight loss and cavitary lesions were more common (P < .01 for both comparisons) and leukocytosis was less common (P < .01) in patients with PO-CAP. A bacterial pathogen was implicated in only 3 (10%) PO-CAP cases. PCT was <0.25 ng/mL in 19 (63.3%) patients. Although no differences were observed in disease severity or rates of intensive care unit admissions, 30-day mortality was significantly higher in PO-CAP vs B-CAP (40.0% vs 11.7%; P < .01). Conclusions. Although there is substantial overlap, PO-CAP is a clinical entity distinct from B-CAP; a bacterial cause was identified in only 10% of patients. Our study has important implications for the clinical recognition of patients with PO-CAP, the role of microorganisms as etiologic agents, and the use of antibiotic therapy. Oxford University Press 2016-04-15 2016-02-21 /pmc/articles/PMC4803103/ /pubmed/26908806 http://dx.doi.org/10.1093/cid/civ1212 Text en © The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com. This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
spellingShingle Articles and Commentaries
Abers, Michael S.
Sandvall, Barcleigh P.
Sampath, Rahul
Zuno, Carlo
Uy, Natalie
Yu, Victor L.
Stager, Charles E.
Musher, Daniel M.
Postobstructive Pneumonia: An Underdescribed Syndrome
title Postobstructive Pneumonia: An Underdescribed Syndrome
title_full Postobstructive Pneumonia: An Underdescribed Syndrome
title_fullStr Postobstructive Pneumonia: An Underdescribed Syndrome
title_full_unstemmed Postobstructive Pneumonia: An Underdescribed Syndrome
title_short Postobstructive Pneumonia: An Underdescribed Syndrome
title_sort postobstructive pneumonia: an underdescribed syndrome
topic Articles and Commentaries
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4803103/
https://www.ncbi.nlm.nih.gov/pubmed/26908806
http://dx.doi.org/10.1093/cid/civ1212
work_keys_str_mv AT abersmichaels postobstructivepneumoniaanunderdescribedsyndrome
AT sandvallbarcleighp postobstructivepneumoniaanunderdescribedsyndrome
AT sampathrahul postobstructivepneumoniaanunderdescribedsyndrome
AT zunocarlo postobstructivepneumoniaanunderdescribedsyndrome
AT uynatalie postobstructivepneumoniaanunderdescribedsyndrome
AT yuvictorl postobstructivepneumoniaanunderdescribedsyndrome
AT stagercharlese postobstructivepneumoniaanunderdescribedsyndrome
AT musherdanielm postobstructivepneumoniaanunderdescribedsyndrome